Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 30 μg ethinylestradiol/75 μg gestodene, on lipid metabolism in an open randomized trial
Brill, K.; Then, A.; Beisiegel, U.; Jene, A.; Wunsch, C.; Leidenberger, F.
Contraception (Stoneham) 54(5): 291-297
1996
ISSN/ISBN: 0010-7824 Document Number: 318851
Document emailed within 1 workday
Related Documents
Endrikat, J.; Jaques, M.A.; Mayerhofer, M.; Pelissier, C.; Müller, U.; Düsterberg, B. 1995: A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 20 micrograms ethinylestradiol/150 micrograms desogestrel, with respect to efficacy, cycle control and tolerance Contraception 52(4): 229-235Lete, I.; Morales, P. 1997: Inhibition of follicular growth by two different oral contraceptives (monophasic and triphasic) containing ethinylestradiol and gestodene European Journal of Contraception and Reproductive Health Care: the Official Journal of the European Society of Contraception 2(3): 187-191
Lüdicke, F.; Gaspard, U.J.; Demeyer, F.; Scheen, A.; Lefebvre, P. 2002: Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism Contraception 66(6): 411-415
Omsjø, I.H.; Oian, P.; Maltau, J.M.; Osterud, B. 1989: Effects of two triphasic oral contraceptives containing ethinylestradiol plus levonorgestrel or gestodene on blood coagulation and fibrinolysis Acta Obstetricia et Gynecologica Scandinavica 68(1): 27-30
Uchikova, E.; Pehlivanov, B. 2008: Effect of two low-dose gestodene containing monophasic oral contraceptives on hemostasis in Bulgarian women Expert Opinion on PharmacoTherapy 9(11): 1839-1844
Lech, M.M.; Swiatek, E.J. 2004: The effectiveness and acceptability of oral contraceptives (Logest), containing 20 micrograms ethinylestradiol and 75 micrograms gestodene Ginekologia Polska 75(3): 209-214
Caruso, S.; Agnello, C.; Intelisano, G.; Farina, M.; Di Mari, L.; Cianci, A. 2004: Sexual behavior of women taking low-dose oral contraceptive containing 15 microg ethinylestradiol/60 microg gestodene Contraception 69(3): 237-240
Zhang, C.; Li, H.; Xiong, X.; Zhai, S.; Wei, Y.; Zhang, S.; Zhang, Y.; Xu, L.; Liu, L. 2017: An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch Drug Design Development and Therapy 11: 725-731
Weber-Diehl, F.; Lehnert, J.; Lachnit, U. 1993: Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial Contraception 48(4): 291-301
Loncar, D.; Milosević-Djordjević, O.; Zivanović, A.; Grujicić, D.; Arsenijević, S. 2004: Effect of a low-dose ethinylestradiol and gestodene in combination on the frequency of micronuclei in human peripheral blood lymphocytes of healthy women in vivo Contraception 69(4): 327-331
Heger-Mahn, D.; Warlimont, C.; Faustmann, T.; Gerlinger, C.; Klipping, C. 2004: Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers European Journal of Contraception and Reproductive Health Care: the Official Journal of the European Society of Contraception 9(3): 173-181
Taneepanichskul, S.; Kriengsinyot, R.; Jaisamrarn, U. 2002: A comparison of cycle control, efficacy, and side effects among healthy Thai women between two low-dose oral contraceptives containing 20 microg ethinylestradio1/75 microg gestodene (Meliane) and 30 microg ethinylestradio1/75 microg gestodene (Gynera) Contraception 66(6): 407-409
Jaithitivit, L.; Jaisamrarn, U.; Taneepanichskul, S. 2012: Cycle control, safety and acceptability of a new oral contraceptive containing ethinylestradiol 15 micrograms and gestodene 60 micrograms Journal of the Medical Association of Thailand 95(5): 630-635
Hammerstein, J.; Daume, E.; Simon, A.; Winkler, U.H.; Schindler, A.E.; Back, D.J.; Ward, S.; Neiss, A. 1993: Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol Contraception 47(3): 263-281
Burness, C.B. 2015: Extended-Cycle Levonorgestrel/Ethinylestradiol and Low-Dose Ethinylestradiol (Seasonique(®)): a Review of its use as an Oral Contraceptive Drugs 75(9): 1019-1026
Rubio-lotvin, B.; Ruiz-moreno, J.A.; Gonzalez-ansorena, R. 1992: Desogestrel-ethinylestradiol, an oral monophasic contraceptive. Clinical and lipid metabolic effects: a 5-year experience Advances in Contraceptive Delivery Systems: Cds 8(1-2): 75-88
Lepot, M.R.; Gaspard, U.J. 1987: Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene International Journal of Fertility 32 Suppl: 15-20
Tantbirojn, P.; Taneepanichskul, S. 2002: Clinical comparative study of oral contraceptives containing 30 microg ethinylestradiol/150 microg levonorgestrel, and 35 microg ethinylestradiol/250 microg norgestimate in Thai women Contraception 66(6): 401-405
Bilotta, P.; Favilli, S. 1988: Clinical evaluation of a monophasic ethinylestradiol/desogestrel-containing oral contraceptive Arzneimittel-Forschung 38(7): 932-934
Marr, J.; Gerlinger, C.; Kunz, M. 2012: A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen European Journal of Obstetrics Gynecology and Reproductive Biology 162(1): 91-95